US SEC Filings Daily Market Digest — March 02, 2026
Across 327 SEC filings for March 2, 2026, mixed sentiment dominates (appearing in 15+ filings like Norwegian Cruise, Venture Global, Ruger), with revenue growth strong in energy (Venture Global +177% YoY to $13.8B, Kosmos Q4 +4% QoQ) and biotech but profitability pressures evident (Ruger FY net loss vs prior profit, WhiteHorse NII -29.8% YoY). Biotech shines with positive Phase 3 data (DBV 46.6% responders, United Therapeutics 55% risk reduction) and catalysts into H1 2026 (BLA submissions, PDUFA Mar 20). M&A activity surges (Warner Bros $81B deal, Malibu Boats accretive acquisition at 7.2x EBITDA, HBT $1.8B assets), alongside capital returns (ADMA $200M buybacks, Klaviyo $500M program). Period trends show YoY revenue acceleration in 20+ cos (avg +20-50% in LNG/pharma) but margin compression in 10+ (avg -100-200bps consumer/manufacturing). Insider sales at Coca-Cola Europacific (execs sold $1.4M) contrast buybacks signaling conviction elsewhere. Forward guidance mixed: flat yields (Norwegian), $5.2-5.8B EBITDA (Venture), but Whirlpool EPS cut ~$1. Implications favor selective longs in biotech/energy catalysts, caution consumer/retail amid traffic declines.